Not admitted · Outside the five areas

Gilead's twice-yearly injectable lenacapavir showed zero HIV infections among 2,134 women in the PURPOSE 1 trial (Uganda, South Africa). The author says HIV could be stopped globally but predicts it will not be, citing the $42,250 price.

Outside the five area definitions in areas.json: not a regulatory decision, trial outcome, company or market outcome, payer or policy decision, or practice adoption about drugs, devices or treatments in psychiatry, or about payment for and access to them. The registry applies the same test when it consolidates proposed events.